Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 500
- Avg volume
- —
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- —
- Beta
- —
- Analysts
- —
- Price target
- —
Company profile
AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada. It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform. The company's pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product base...
Show more
AREV Life Sciences Global Corp. operates as an early-stage life science discovery company in Canada. It is involved in the extraction of compounds for consumption and topical use; clinical nutrition business; and Medicine Merchant, a technology platform. The company's pipeline products include SUS-TAINN, a superior utility supplementation therapeutic agent for indicated nutritional needs; and RES-TORE, a product based on organic plant nutrition for patients with overt clinical need for rational enhanced caloric intake and micronutrient supplementation. It also develops edible oils, moringa, hops, cannabis sativa, pharma, sea cucumber, ginseng, and functional fungi ingredients; and anti-virals and phytomedicinalization. In addition, the company flash-freezes active ingredients, oils, and oleoresins for use as ingredients in food, nutraceuticals, and other consumer products. The company was formerly known as AREV NanoTec Brands Inc. and changed its name to AREV Life Sciences Global Corp. in August 2021. AREV Life Sciences Global Corp. is based in Coquitlam, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 604 803 8439
- Website
- https://www.arevlifesciences.com
- Address
- 18 - 91 Golden Drive, Coquitlam, Canada
Latest news
No headlines yet.